Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,556.00GBp
22 Jan 2019
Change (% chg)

-- (--)
Prev Close
5,556.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,041,097
52-wk High
6,432.48
52-wk Low
4,544.50

Select another date:

Mon, Jan 7 2019

Photo

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British pharmaceuticals firm is seeking to grow its business.

AstraZeneca picks Baselga to lead oncology R&D in growth plan

AstraZeneca said on Monday it had hired José Baselga to head research and development in oncology, an area where the British pharmaceuticals firm is seeking to grow its business.

UPDATE 2-AstraZeneca picks Baselga to lead oncology R&D in growth plan

* Creates R&D units for biopharmaceuticals and oncology (Adds comments from José Baselga, updates shares)

AstraZeneca appoints Baselga to head R&D for oncology

Jan 7 AstraZeneca Plc has appointed José Baselga to head research and development for oncology as it looks to align the unit with its commercial operations to drive growth.

AstraZeneca's ovarian cancer and anaemia treatments meet goals in late-stage studies

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anaemia treatments met their goals in three separate late stage trials.

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies

British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials.

AstraZeneca's ovarian cancer and anemia treatments meet goals in late-stage studies

Dec 20 British drugmaker AstraZeneca on Thursday said its ovarian cancer and anemia treatments met their goals in three separate late stage trials.

AstraZeneca's ovarian cancer drug gets FDA nod as maintenance treatment

Dec 19 The U.S. Food and Drug Administration approved AstraZeneca Plc's cancer drug developed along with Merck & Co as a first-line maintenance treatment for adults with a form of ovarian cancer, the companies said on Wednesday.

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON, Dec 18 China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Select another date: